Menatetrenone

DB12148InvestigationalSmall molecule

Menatetrenone is a form of vitamin K2 which is used in the treatment of osteoporosis to stimulate osteogenesis. Menatetrenone has been used in trials studying the treatment of Diabetes, Osteoporosis, Prediabetic State, and Hepatocellular Carcinoma.

Mechanism: Pharmacologically active on Cruzipain
Curator reviewed
Formula / weight: C₃₁H₄₀O₂ · 444.659 g/mol (avg)
Also known as: menatetranone

Resolves to

Compound

UNII27Y876D139CAS863-61-6ChEMBLCHEMBL259223ChEBI78277PubChem5282367

Clinical / RWD

RxNorm29495ATCM05BX08

Structure

InChIKeyDKHGMERMDICWDU-GHDNBGIDSA-NSMILES[H]\C(CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC1=C(C)C(=O)C2=CC=CC=C2C1=O)=C(\C)CCC=C(C)C

Targets

P25779Cruzipain

What you can answer from here — as of May 30, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Drug interactionStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

3Marketed productsAcross 2 countries and 3 labellers

1ATC codeIncluding every combination product, plus 15 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Menatetrenone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account